Benign Prostatic Hyperplasia Therapeutics Market - Forecast(2024 - 2030)

Report Code: HCR 88941 Report Format: PDF + Excel

$ 4250 Single User License ?
$ 5900 Corporate User License ?

Table of Contents

1. Benign Prostatic Hyperplasia Therapeutics Market - Overview
        1.1 Definitions and Scope
2. Benign Prostatic Hyperplasia Therapeutics Market - Executive summary
        2.1 Market Revenue, Market Size and Key Trends by Company
        2.2 Key Trends by type of Application
        2.3 Key Trends segmented by Geography
3. Benign Prostatic Hyperplasia Therapeutics Market
        3.1 Comparative analysis
            3.1.1 Product Benchmarking - Top 10 companies
            3.1.2 Top 5 Financials Analysis
            3.1.3 Market Value split by Top 10 companies
            3.1.4 Patent Analysis - Top 10 companies
            3.1.5 Pricing Analysis
4. Benign Prostatic Hyperplasia Therapeutics Market - Startup companies Scenario Premium
        4.1 Top 10 startup company Analysis by
            4.1.1 Investment
            4.1.2 Revenue
            4.1.3 Market Shares
            4.1.4 Market Size and Application Analysis
            4.1.5 Venture Capital and Funding Scenario
5. Benign Prostatic Hyperplasia Therapeutics Market - Industry Market Entry Scenario Premium
        5.1 Regulatory Framework Overview
        5.2 New Business and Ease of Doing business index
        5.3 Case studies of successful ventures
        5.4 Customer Analysis - Top 10 companies
6. Benign Prostatic Hyperplasia Therapeutics Market Forces
        6.1 Drivers
        6.2 Constraints
        6.3 Challenges
        6.4 Porters five force model
            6.4.1 Bargaining power of suppliers
            6.4.2 Bargaining powers of customers
            6.4.3 Threat of new entrants
            6.4.4 Rivalry among existing players
            6.4.5 Threat of substitutes
7. Benign Prostatic Hyperplasia Therapeutics Market -Strategic analysis
        7.1 Value chain analysis
        7.2 Opportunities analysis
        7.3 Product life cycle
        7.4 Suppliers and distributors Market Share
8. Benign Prostatic Hyperplasia Therapeutics Market - By Therapeutic Class (Market Size -$Million / $Billion)

8.1 Alpha Blocker
8.2 5-Alpha Reductase Inhibitor
8.3 Phosphodiesterase 5 Inhibitor
9. Benign Prostatic Hyperplasia Therapeutics Market - By Therapy (Market Size -$Million / $Billion)
9.1 Mono Drug Therapy
9.2 Combination Drug Therapy
10. Benign Prostatic Hyperplasia Therapeutics - By Application (Market Size -$Million / $Billion)
        10.1 Segment type Size and Market Share Analysis
        10.2 Application Revenue and Trends by type of Application
        10.3 Application Segment Analysis by Type
11. Benign Prostatic Hyperplasia Therapeutics- By Geography (Market Size -$Million / $Billion)
        11.1 Benign Prostatic Hyperplasia Therapeutics Market - North America Segment Research
        11.2 North America Market Research (Million / $Billion)
            11.2.1 Segment type Size and Market Size Analysis
            11.2.2 Revenue and Trends
            11.2.3 Application Revenue and Trends by type of Application
            11.2.4 Company Revenue and Product Analysis
            11.2.5 North America Product type and Application Market Size
                  11.2.5.1 U.S
                  11.2.5.2 Canada
                  11.2.5.3 Mexico
                  11.2.5.4 Rest of North America
        11.3 Benign Prostatic Hyperplasia Therapeutics- South America Segment Research
        11.4 South America Market Research (Market Size -$Million / $Billion)
            11.4.1 Segment type Size and Market Size Analysis
            11.4.2 Revenue and Trends
            11.4.3 Application Revenue and Trends by type of Application
            11.4.4 Company Revenue and Product Analysis
            11.4.5 South America Product type and Application Market Size
                  11.4.5.1 Brazil
                  11.4.5.2 Venezuela
                  11.4.5.3 Argentina
                  11.4.5.4 Ecuador
                  11.4.5.5 Peru
                  11.4.5.6 Colombia
                  11.4.5.7 Costa Rica
                  11.4.5.8 Rest of South America
        11.5 Benign Prostatic Hyperplasia Therapeutics- Europe Segment Research
        11.6 Europe Market Research (Market Size -$Million / $Billion)
            11.6.1 Segment type Size and Market Size Analysis
            11.6.2 Revenue and Trends
            11.6.3 Application Revenue and Trends by type of Application
            11.6.4 Company Revenue and Product Analysis
            11.6.5 Europe Segment Product type and Application Market Size
                  11.6.5.1 U.K
                  11.6.5.2 Germany
                  11.6.5.3 Italy
                  11.6.5.4 France
                  11.6.5.5 Netherlands
                  11.6.5.6 Belgium
                  11.6.5.7 Denmark
                  11.6.5.8 Spain
                  11.6.5.9 Rest of Europe
        11.7 Benign Prostatic Hyperplasia Therapeutics - APAC Segment Research
        11.8 APAC Market Research (Market Size -$Million / $Billion)
            11.8.1 Segment type Size and Market Size Analysis
            11.8.2 Revenue and Trends
            11.8.3 Application Revenue and Trends by type of Application
            11.8.4 Company Revenue and Product Analysis
            11.8.5 APAC Segment - Product type and Application Market Size
                  11.8.5.1 China
                  11.8.5.2 Australia
                  11.8.5.3 Japan
                  11.8.5.4 South Korea
                  11.8.5.5 India
                  11.8.5.6 Taiwan
                  11.8.5.7 Malaysia
                  11.8.5.8 Hong kong
                  11.8.5.9 Rest of APAC
        11.9 Benign Prostatic Hyperplasia Therapeutics - Middle East Segment and Africa Segment Research
        11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
            11.10.1 Segment type Size and Market Size Analysis
            11.10.2 Revenue and Trend Analysis
            11.10.3 Application Revenue and Trends by type of Application
            11.10.4 Company Revenue and Product Analysis
            11.10.5 Middle East Segment Product type and Application Market Size
                  11.10.5.1 Israel
                  11.10.5.2 Saudi Arabia
                  11.10.5.3 UAE
            11.10.6 Africa Segment Analysis
                  11.10.6.1 South Africa
                  11.10.6.2 Rest of Middle East & Africa
12. Benign Prostatic Hyperplasia Therapeutics Market - Entropy
        12.1 New product launches
        12.2 M&A s, collaborations, JVs and partnerships
13. Benign Prostatic Hyperplasia Therapeutics Market - Industry / Segment Competition landscape Premium
        13.1 Market Share Analysis
            13.1.1 Market Share by Country- Top companies
            13.1.2 Market Share by Region- Top 10 companies
            13.1.3 Market Share by type of Application - Top 10 companies
            13.1.4 Market Share by type of Product / Product category- Top 10 companies
            13.1.5 Market Share at global level - Top 10 companies
            13.1.6 Best Practises for companies
14. Benign Prostatic Hyperplasia Therapeutics Market - Key Company List by Country Premium
15. Benign Prostatic Hyperplasia Therapeutics Market Company Analysis
        15.1 Market Share, Company Revenue, Products, M&A, Developments
        15.2 Abbott Laboratory
        15.3 Allergan Plc
        15.4 Astellas Pharma Inc
        15.5 Boehringer Ingelheim Pharma Gmbh Co. Kg
        15.6 Eli Lilly And Company
        15.7 Glaxosmithkline Plc
        15.8 Merck Co , Inc
        15.9 Pfizer Inc
        15.10 Sanofi
        15.11 Teva Pharmaceutical Industry Limited
        15.12 Company 12
        15.13 Company 13 & More

*Financials would be provided on a best efforts basis for private companies

16. Benign Prostatic Hyperplasia Therapeutics Market - Appendix
        16.1 Abbreviations
        16.2 Sources
17. Benign Prostatic Hyperplasia Therapeutics Market - Methodology
        17.1 Research Methodology
            17.1.1 Company Expert Interviews
            17.1.2 Industry Databases
            17.1.3 Associations
            17.1.4 Company News
            17.1.5 Company Annual Reports
            17.1.6 Application Trends
            17.1.7 New Products and Product database
            17.1.8 Company Transcripts
            17.1.9 R&D Trends
            17.1.10 Key Opinion Leaders Interviews
            17.1.11 Supply and Demand Trends

LIST OF TABLES

1.Global Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
1.1 Alpha Blocker Market 2023-2030 ($M) - Global Industry Research
1.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Global Industry Research
1.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Global Industry Research
2.Global Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
2.1 Mono Drug Therapy Market 2023-2030 ($M) - Global Industry Research
2.2 Combination Drug Therapy Market 2023-2030 ($M) - Global Industry Research
3.Global Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 (Volume/Units)
3.1 Alpha Blocker Market 2023-2030 (Volume/Units) - Global Industry Research
3.2 5-Alpha Reductase Inhibitor Market 2023-2030 (Volume/Units) - Global Industry Research
3.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 (Volume/Units) - Global Industry Research
4.Global Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 (Volume/Units)
4.1 Mono Drug Therapy Market 2023-2030 (Volume/Units) - Global Industry Research
4.2 Combination Drug Therapy Market 2023-2030 (Volume/Units) - Global Industry Research
5.North America Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
5.1 Alpha Blocker Market 2023-2030 ($M) - Regional Industry Research
5.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
5.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Regional Industry Research
6.North America Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
6.1 Mono Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
6.2 Combination Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
7.South America Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
7.1 Alpha Blocker Market 2023-2030 ($M) - Regional Industry Research
7.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
7.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Regional Industry Research
8.South America Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
8.1 Mono Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
8.2 Combination Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
9.Europe Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
9.1 Alpha Blocker Market 2023-2030 ($M) - Regional Industry Research
9.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
9.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Regional Industry Research
10.Europe Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
10.1 Mono Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
10.2 Combination Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
11.APAC Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
11.1 Alpha Blocker Market 2023-2030 ($M) - Regional Industry Research
11.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
11.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Regional Industry Research
12.APAC Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
12.1 Mono Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
12.2 Combination Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
13.MENA Benign Prostatic Hyperplasia Therapeutic Market, By Therapeutic Class Market 2023-2030 ($M)
13.1 Alpha Blocker Market 2023-2030 ($M) - Regional Industry Research
13.2 5-Alpha Reductase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
13.3 Phosphodiesterase 5 Inhibitor Market 2023-2030 ($M) - Regional Industry Research
14.MENA Benign Prostatic Hyperplasia Therapeutic Market, By Therapy Market 2023-2030 ($M)
14.1 Mono Drug Therapy Market 2023-2030 ($M) - Regional Industry Research
14.2 Combination Drug Therapy Market 2023-2030 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
2.Canada Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
3.Mexico Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
4.Brazil Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
5.Argentina Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
6.Peru Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
7.Colombia Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
8.Chile Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
9.Rest of South America Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
10.UK Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
11.Germany Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
12.France Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
13.Italy Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
14.Spain Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
15.Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
16.China Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
17.India Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
18.Japan Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
19.South Korea Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
20.South Africa Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2023-2030 ($M)
21.North America Benign Prostatic Hyperplasia Therapeutics By Application
22.South America Benign Prostatic Hyperplasia Therapeutics By Application
23.Europe Benign Prostatic Hyperplasia Therapeutics By Application
24.APAC Benign Prostatic Hyperplasia Therapeutics By Application
25.MENA Benign Prostatic Hyperplasia Therapeutics By Application
26.Abbott Laboratory, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Allergan Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Astellas Pharma Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Boehringer Ingelheim Pharma Gmbh Co. Kg, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Eli Lilly And Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Sanofi, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Teva Pharmaceutical Industry Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)

Table of Contents

Report Options Request Sample Data